Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03473639 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03473639 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 13 participants.
The verdict
NCT03473639, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC), in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy.
Interventions
- DRUG Capecitabine
- DRUG Entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03473639
The ClinicalTrials.gov registry entry for NCT03473639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT03473639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03473639 about?
NCT03473639 is a clinical study titled "A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy". The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC), in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after n...
What is the current status of trial NCT03473639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-01-29. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT03473639?
The interventions under investigation include: Capecitabine (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT03473639?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.